Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer

Rectal Cancer Clinical Trial

— TRUST  

Official title:

Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03085992
• Other study ID #: TRUST
• Secondary ID: 2011-003340-45
• Status: Completed
• Phase: Phase 2
• First received: June 8, 2016
• Last updated: March 12, 2018
• Start date: March 2012
• Est. completion date: March 12, 2018

Study information

• Verified date: March 2018
• Source: Azienda Ospedaliero, Universitaria Pisana
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study includes patients affected by advanced and resectable rectal adenocarcinoma. It provides an induction chemotherapy with FOLFOXIRI regimen plus Bevacizumab followed by Chemoradiotherapy plus Bevacizumab. Surgery with total mesorectal incision must be performed within 7-9 weeks after this last treatment. The protocol will be evaluate the disease free survival at two years. Translational analyses will be performed to show the presence of VEGF polymorphism, CD133 surface markers on colorectal CSCs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: March 12, 2018
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically proven diagnosis of rectal adenocarcinoma. Diagnosis obtained by a biopsy technique which leaves the major portion of the tumor intact.

• Locally advanced, resectable disease defined by the presence of at least one of the following features: tumour extending to within 1 mm of or beyond the mesorectal fascia (ie, circumferential radial margin threatened or involved); lower third (= 6 cm from the anal verge) cT3 tumours; tumour extending 5 mm or more into perirectal fat; T4 tumour (ie, invading surrounding structures or peritoneum); clinical stage III disease (T1-4, N1-2), with the definition of a clinically positive lymph node being any node = 1.0 cm;

• Distal border of the tumor must be located < 12 cm from the anal verge.

• No evidence of metastatic disease by CT scan of the chest and abdomen and total body PET-CT scan.

• Tumor must be amenable to curative resection (curative resection can include pelvic exenteration).

• No history of invasive rectal malignancy, regardless of disease-free interval.

• No other rectal cancers (i.e., sarcoma, lymphoma, carcinoid, squamous cell carcinoma, or cloacogenic carcinoma) or synchronous colon cancer.

• No clear indication of involvement of the pelvic side walls by imaging.

• Age between 18 and 75 years.

• ECOG Performance status < 2 if age < 70 years and = 0 if age 71-75 years.

• Life expectancy of at least 5 years (excluding diagnosis of cancer).

• Hematopoietic: absolute neutrophil count = 1,000/mm3; platelet count = 100,000/mm3; haemoglobin level = 10 g/dL.

• Hepatic: total bilirubin = 1.5 times upper limit of normal (ULN); alkaline phosphatase = 2 times ULN; AST = 2 times ULN. [Note: *If AST>ULN, serologic testing for Hepatitis B and C must be negative].

• Renal: creatinine clearance > 50 mL/min; no renal disease that would preclude study treatment or follow-up.

• Written informed consent to experimental treatment and pharmacogenomic analyses.

Exclusion Criteria:

• Previous treatment with oxaliplatin, irinotecan or bevacizumab. Previous 5-fluorouracil or capecitabine treatment is allowed.

• Previous pelvic radiation therapy.

• Hepatic disease that would preclude study treatment or follow-up; uncontrolled coagulopathy; history of viral hepatitis or other chronic liver disease.

• Cardiovascular disease that would preclude study treatment or follow-up; New York Heart Association class III or IV heart disease; active ischemic heart disease; myocardial infarction within the past 6 months; symptomatic arrhythmia; uncontrolled hypertension.

• Lack of upper gastrointestinal tract integrity or malabsorption syndrome; active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic).

• Pregnant or lactating women. Fertile patients must use effective contraception (i.e double-barrier contraceptive measures, oral contraception or avoidance of intercourse during the study and for 30 days after surgery).

• Patients with prior malignancies (with the exception of rectal cancer), including invasive colon cancer, are eligible provided they have been disease-free for = 5 years and are deemed by their physician to be at low risk for recurrence.

• Other malignancy within the past 5 years with the exception of effectively treated squamous cell or basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum.

• Known hypersensitivity to fluorouracil, oxaliplatin or irinotecan or to Chinese hamster ovary cell proteins.

• Clinically significant peripheral neuropathy (i.e., neurosensory or neuromotor toxicity = grade 2).

• Psychiatric or addictive disorders, or other conditions that, in the opinion of the investigator, would preclude study participation

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• FOLFOXIRI plus Bevacizumab
BEVACIZUMAB 5 mg/kg over 30 minutes, day 1 IRINOTECAN 165 mg/sqm IV over 1-h, day 1 OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months).

Other:
• Chemoradiotherapy plus Bevacizumab
FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment; EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks; BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles).

Locations

Country	Name	City	State
Italy	Irccs Istituto Oncologico Veneto	Padova
Italy	Polo Oncologico Area Vasta Nord Ovest	Pisa
Italy	ausl5 di Pisa	Pontedera
Italy	Dipartimento Oncologico AUSL 7	Siena

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliero, Universitaria Pisana

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival rate at 2 years	Disease-free survival is defined as time from study entry until progression of disease (according to RECIST 1.1) or death from any cause. Patients who are alive without having progressed at the end of the study will be censored at their last radiological assessment.	Up to 2 years
Secondary	Response rate	Response rate is defined as the fraction of treated patients who achieve a response as defined according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria vers. 1.1.	Up to 2 years
Secondary	Toxicity Rate	Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled subjects, experiencing treatment-related adverse events as assessed by National Cancer Institute Common Toxicity Criteria (version 3.0), during induction and concomitant chemoradiotherapy	Up to 2 years
Secondary	Overall survival	Overall survival is defined as the time from study entry until death from any cause. Patients who are alive at the end of the study will be censored at that point.	Up to 2 years
Secondary	Pathological complete response rate	Pathological complete response rate is defined as the fraction of treated patients who achieve pathological response after treatment	Up to 2 years